SGLT2 Inhibitors

The next issue of The Medical Letter (1479; October 12, 2015) will include an article on 2 recent reports about SGLT2 inhibitors, one favorable and one a little worrisome. The SGLT2 inhibitors, which are used to treat diabetes, have been proliferating rapidly since 2013, when canagliflozin (Invokana) was the first to be approved. Dapagliflozin (Farxiga) […]

Live vs Inactivated Influenza Vaccine

The next issue of The Medical Letter begins with an article on influenza vaccine for the 2015-2016 season. Only one paragraph touches on the choice between the standard inactivated vaccine given by injection and the live attenuated vaccine, which is sprayed intranasally. Last year the CDC Advisory Committee on Immunization Practices recommended use of the […]

A New Drug for Heart Failure

Since our most recent issue (August 3, 2015; 1474) includes an article on a new drug, sacubitril/valsartan (Entresto), for treatment of heart failure, we have asked our Contributing Editor, Dan M. Roden, MD, to be our guest blogger this week. Dr. Roden is Vice-Chancellor for Personalized Medicine and Professor of Medicine and Pharmacology at Vanderbilt […]

Drugs for Insomnia

Since our July 6th issue includes an article on Drugs for Insomnia, we have invited our Contributing Editor, Carl W. Bazil, MD, PhD, to be our guest blogger this week. Dr. Bazil is Director of the Epilepsy and Sleep Division of the Department of Neurology at Columbia University Medical Center. In addition to clinical care […]

Weight Loss Diets

The next issue (June 22, 2015) of The Medical Letter will include an article on Saxenda, a new formulation of the GLP-1 receptor agonist liraglutide that has been approved by the FDA for chronic weight management. Liraglutide was already available as Victoza for treatment of type 2 diabetes, and the observation that diabetes patients treated […]

The Medicare Prescription Champion

The May 1, 2015 issue of The New York Times included an article on the top 10 drugs prescribed in 2013 under Medicare Part D, listed by cost. The drug that cost Medicare the most was the proton pump inhibitor Nexium ($2.53 billion), and we will discuss that in an upcoming article of The Medical […]

Ivabradine (Corlanor) – Mixed Results in Clinical Trials

The next issue of The Medical Letter (1469; May 25, 2015) will include an article on ivabradine (Corlanor – Amgen), a new drug for treatment of heart failure. The FDA-approved indication for its use is actually much more complicated. It specifies that the drug is approved to reduce the risk of hospitalization for worsening heart […]


Get every new post delivered to your Inbox.

Join 1,277 other followers